BDBM224231 3-{6-(3- chlorophenyl)-8- (hexahydro-4h- furo[3,2-b]pyrrol-4- yl)-7-[(trans-4- methylcyclohexyl) methyl]-7h-purin-2-yl}- 1,2,4-oxadiazol- 5(4h)-one::US9540377, 16.150

SMILES C[C@H]1CC[C@H](Cn2c(N3CCC4OCCC43)nc3nc(-c4noc(=O)[nH]4)nc(-c4cccc(Cl)c4)c32)CC1

InChI Key InChIKey=DOGLHDRNXYDXCI-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 224231   

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandChemical structure of BindingDB Monomer ID 224231BDBM224231(US9540377, 16.150 | 3-{6-(3- chlorophenyl)-8- (hex...)
Affinity DataIC50: 45.0nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2018
Entry Details
US Patent